Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far
Authors
Keywords
-
Journal
RHEUMATOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2017-11-16
DOI
10.1093/rheumatology/kex434
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
- (2016) Meghna Jani et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
- (2016) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug
- (2016) Jacques-Eric Gottenberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels
- (2016) Meghna Jani et al. RHEUMATOLOGY
- Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis: Initiating Disease-Modifying Antirheumatic Drugs
- (2015) Seoyoung C. Kim et al. AMERICAN JOURNAL OF MEDICINE
- Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial(STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)
- (2015) Bruno Fautrel et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis
- (2015) Jasvinder A Singh et al. LANCET
- pANCA Positivity Predicts Lower Clinical Response to Infliximab Therapy among Patients with IBD
- (2015) Douglas L. Nguyen et al. SOUTHERN MEDICAL JOURNAL
- Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
- (2015) N. van Herwaarden et al. BMJ-British Medical Journal
- Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial
- (2015) N. van Herwaarden et al. BMJ-British Medical Journal
- Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis
- (2015) Meghna Jani et al. Arthritis & Rheumatology
- What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort
- (2014) K Takase et al. ANNALS OF THE RHEUMATIC DISEASES
- Drug-associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center
- (2014) F. Ortiz-Sanjuan et al. JOURNAL OF RHEUMATOLOGY
- Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis
- (2014) Motoaki Hoshino et al. Modern Rheumatology
- Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database
- (2014) Paul de Boissieu et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database
- (2014) Guillaume Moulis et al. RHEUMATOLOGY
- Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study
- (2013) Wei-Sheng Chung et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
- (2013) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
- (2013) Josef S Smolen et al. LANCET
- The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
- (2013) M. Jani et al. RHEUMATOLOGY
- The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure
- (2013) S. B. Krintel et al. RHEUMATOLOGY
- Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
- (2012) Fabien B Vincent et al. ANNALS OF THE RHEUMATIC DISEASES
- Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
- (2012) Charlotte L Krieckaert et al. ANNALS OF THE RHEUMATIC DISEASES
- The role of biosimilars in the treatment of rheumatic diseases
- (2012) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
- (2012) Sandra Garcês et al. ANNALS OF THE RHEUMATIC DISEASES
- Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden
- (2012) C.M. Grönhagen et al. BRITISH JOURNAL OF DERMATOLOGY
- Thromboembolic events and anti‐tumor necrosis factor therapies
- (2012) P.L. Masson INTERNATIONAL IMMUNOPHARMACOLOGY
- Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register
- (2011) R. Davies et al. ANNALS OF THE RHEUMATIC DISEASES
- Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients
- (2011) A Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study
- (2011) L. A. Korswagen et al. ARTHRITIS AND RHEUMATISM
- Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
- (2011) Klaus Bendtzen ARTHRITIS AND RHEUMATISM
- Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction
- (2011) J.H.O. Hoffmann et al. BRITISH JOURNAL OF DERMATOLOGY
- Takayasu’s arteritis progression on anti-TNF biologics: a case series
- (2011) Mohammed Osman et al. CLINICAL RHEUMATOLOGY
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
- (2011) D. Pascual-Salcedo et al. RHEUMATOLOGY
- Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study
- (2011) Naoichiro Yukawa et al. ARTHRITIS RESEARCH & THERAPY
- Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
- (2011) Emilie Ducourau et al. ARTHRITIS RESEARCH & THERAPY
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
- (2010) A. Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Drug-induced lupus: An update
- (2010) Uriel Katz et al. AUTOIMMUNITY REVIEWS
- Onset of Wegener's granulomatosis during therapy with golimumab for rheumatoid arthritis: a rare adverse event?
- (2010) K. Parekh et al. RHEUMATOLOGY
- Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
- (2009) A. Vultaggio et al. ALLERGY
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
- Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
- (2009) Paul Emery et al. ARTHRITIS AND RHEUMATISM
- Cutaneous Vasculitis Associated With Interferon β-1b Treatment for Multiple Sclerosis
- (2009) Jarmila Szilasiová et al. CLINICAL NEUROPHARMACOLOGY
- Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study
- (2008) B J F van den Bemt et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
- (2008) J Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
- (2008) R Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents
- (2007) Michelle F. Costa et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started